Pfizer Inc. recalls DOBUTamine Injection
- Published
- 2 Jul 2025
- Units affected
- 98,410 vials
- Agency
- FDA
- Country
- United States
The hazard
Discoloration; discolored solution from cracked vials
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
DOBUTamine Injection, USP, 250 mg/20 mL (12.5 mg/mL), 20 mL per Single-dose Vial, carton of 10 Fliptop Vials, Rx only, For Intravenous Use Only, Made in Italy, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA. NDC Carton: 0409-2344-02; NDC Vial: 0409-2344-62
- Brand / company
- Pfizer Inc.
- Codes / lots
- Lot KA5023, exp 02/28/2026
- Distribution
- Nationwide in the USA
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 2 Jul 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.